
NASDAQHealthcareDrug Manufacturers - General
Latest quote
$8.15
−$0.05 · -0.61%
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Previous close
$8.15
−$0.05 · -0.61%
Regular session · ET · Market data may be delayed.
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Day range
Current $8.15
52-week range
Current $8.15
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
90
Deep Value
Sentiment
59
Mixed
Risk
43
Elevated Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Day range
Current $8.15
52-week range
Current $8.15
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.23B EUR | 7.21B EUR | 6.59B EUR | 6.06B EUR | 4.93B EUR |
| Cost of goods sold | 4.65B EUR | 4.42B EUR | 4.11B EUR | 3.85B EUR | 2.97B EUR |
| Gross profit | 2.58B EUR | 2.79B EUR | 2.48B EUR | 2.21B EUR | 1.96B EUR |
| Research and development | 358.28M EUR | 384.04M EUR | 395.28M EUR | 361.14M EUR | 354.88M EUR |
| Selling, general, and administrative | 1.02B EUR | 1.14B EUR | 1.27B EUR | 1.11B EUR | 1.06B EUR |
| Operating expenses | 1.39B EUR | 1.6B EUR | 1.7B EUR | 1.43B EUR | 1.37B EUR |
| Interest income | 32.66M EUR | 48.05M EUR | 62.43M EUR | 33.86M EUR | 11.55M EUR |
| Interest expense | 600.33M EUR | 773.16M EUR | 516.06M EUR | 444.54M EUR | 233.81M EUR |
| Depreciation and amortization | 432.24M EUR | 437.9M EUR | 446.42M EUR | 410.98M EUR | 359.77M EUR |
| Operating income | 1.19B EUR | 1.19B EUR | 782.32M EUR | 782.44M EUR | 595.06M EUR |
| Net income | 386.13M EUR | 156.92M EUR | 42.32M EUR | 185.04M EUR | 188.73M EUR |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 4, 2016 | 2:1 | — | — |
Stock split | Dec 11, 2012 | 21:20 | — | — |
Stock split | Jul 23, 2012 | 1:2 | — | — |
Stock split | Dec 1, 2011 | 11:10 | — | — |
Effective Jan 4, 2016
2:1
Effective Dec 11, 2012
21:20
Effective Jul 23, 2012
1:2
Effective Dec 1, 2011
11:10
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB14.67M0.14%10.53B USD0.44%$199.54-2.05%
Brandes International ETFBINV7.67M1.41%545.47M USD0.70%$43.195-1.56%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.95M0.13%2.31B USD0.20%$53.96-5.13%
Brandes U.S. Small-Mid Cap Value ETFBSMC2.8M1.67%167.47M USD0.70%$38.27-1.15%
State Street SPDR Portfolio Developed World ex-US ETFSPDW2.63M0.01%40.12B USD0.03%$45.25-3.06%
Capital Group International Core Equity ETFCGIC989.85K0.04%2.48B USD0.54%$32.12-3.34%
ActivePassive International Equity ETFAPIE199.31K0.02%1.02B USD0.45%$34.50-3.28%
Invesco NASDAQ Future Gen 200 ETFQQQS128.55K0.68%17.98M USD0.20%$33.2778-4.35%
iShares Biotechnology ETFIBB
Brandes International ETFBINV
State Street SPDR S&P Kensho New Economies Composite ETFKOMP
Brandes U.S. Small-Mid Cap Value ETFBSMC
State Street SPDR Portfolio Developed World ex-US ETFSPDW
Capital Group International Core Equity ETFCGIC
ActivePassive International Equity ETFAPIE
Invesco NASDAQ Future Gen 200 ETFQQQSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.